 Mark Steele
Concepts (270)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Idiopathic Pulmonary Fibrosis | 19 | 2023 | 451 | 3.200 |
Why?
| | Lung Diseases, Interstitial | 13 | 2023 | 464 | 2.180 |
Why?
| | Idiopathic Interstitial Pneumonias | 5 | 2019 | 41 | 1.240 |
Why?
| | Lung Transplantation | 14 | 2011 | 263 | 0.960 |
Why?
| | Lung | 17 | 2023 | 3664 | 0.640 |
Why?
| | Genetic Predisposition to Disease | 11 | 2019 | 2275 | 0.600 |
Why?
| | Mucin-5B | 7 | 2019 | 175 | 0.600 |
Why?
| | Biopsy | 10 | 2020 | 1079 | 0.520 |
Why?
| | Pulmonary Surfactant-Associated Protein A | 2 | 2019 | 24 | 0.490 |
Why?
| | Machine Learning | 4 | 2019 | 331 | 0.480 |
Why?
| | Pulmonary Surfactant-Associated Protein C | 2 | 2019 | 41 | 0.470 |
Why?
| | Gene Expression Profiling | 5 | 2016 | 1597 | 0.390 |
Why?
| | Proteins | 1 | 2015 | 938 | 0.350 |
Why?
| | Pulmonary Fibrosis | 6 | 2016 | 303 | 0.330 |
Why?
| | Transplants | 1 | 2008 | 36 | 0.330 |
Why?
| | Tissue Donors | 3 | 2011 | 336 | 0.310 |
Why?
| | Sarcoma, Kaposi | 1 | 2008 | 73 | 0.310 |
Why?
| | RNA | 2 | 2019 | 833 | 0.310 |
Why?
| | Middle Aged | 34 | 2021 | 27617 | 0.300 |
Why?
| | Gene Expression Regulation | 2 | 2016 | 2445 | 0.290 |
Why?
| | Polymorphism, Genetic | 4 | 2015 | 642 | 0.290 |
Why?
| | Aged | 25 | 2021 | 19657 | 0.290 |
Why?
| | Bronchiolitis Obliterans | 5 | 2007 | 66 | 0.280 |
Why?
| | Genetic Variation | 4 | 2019 | 926 | 0.270 |
Why?
| | Mutation | 3 | 2012 | 3457 | 0.250 |
Why?
| | Biomarkers | 3 | 2020 | 3588 | 0.240 |
Why?
| | Case-Control Studies | 8 | 2019 | 3171 | 0.240 |
Why?
| | Tomography, X-Ray Computed | 8 | 2019 | 2436 | 0.230 |
Why?
| | Humans | 47 | 2023 | 118974 | 0.220 |
Why?
| | Male | 39 | 2021 | 57801 | 0.220 |
Why?
| | ROC Curve | 4 | 2019 | 473 | 0.210 |
Why?
| | Reproducibility of Results | 4 | 2019 | 2874 | 0.210 |
Why?
| | Dyspnea | 1 | 2023 | 201 | 0.200 |
Why?
| | Female | 36 | 2021 | 61565 | 0.200 |
Why?
| | Cohort Studies | 6 | 2023 | 5116 | 0.180 |
Why?
| | Coinfection | 1 | 2021 | 119 | 0.180 |
Why?
| | DNA Helicases | 2 | 2019 | 131 | 0.160 |
Why?
| | Cellular Senescence | 1 | 2019 | 151 | 0.160 |
Why?
| | Sequence Analysis, RNA | 2 | 2017 | 409 | 0.150 |
Why?
| | Incidence | 2 | 2023 | 2424 | 0.150 |
Why?
| | Adult | 19 | 2021 | 31512 | 0.150 |
Why?
| | Genome-Wide Association Study | 4 | 2019 | 1323 | 0.150 |
Why?
| | Respiratory Tract Infections | 1 | 2021 | 331 | 0.150 |
Why?
| | Desmoplakins | 1 | 2016 | 19 | 0.140 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 300 | 0.140 |
Why?
| | Bronchoscopy | 3 | 2015 | 247 | 0.140 |
Why?
| | HLA-DQ beta-Chains | 1 | 2016 | 61 | 0.140 |
Why?
| | ADAMTS9 Protein | 1 | 2015 | 5 | 0.140 |
Why?
| | Serpin E2 | 1 | 2015 | 5 | 0.140 |
Why?
| | Procollagen N-Endopeptidase | 1 | 2015 | 7 | 0.140 |
Why?
| | Risk Factors | 9 | 2021 | 9000 | 0.140 |
Why?
| | ADAMTS4 Protein | 1 | 2015 | 15 | 0.140 |
Why?
| | HLA-DRB1 Chains | 1 | 2016 | 97 | 0.140 |
Why?
| | Serpins | 1 | 2015 | 26 | 0.140 |
Why?
| | E-Selectin | 1 | 2015 | 52 | 0.140 |
Why?
| | Receptor for Advanced Glycation End Products | 1 | 2015 | 34 | 0.140 |
Why?
| | Cluster Analysis | 2 | 2014 | 481 | 0.130 |
Why?
| | Carbon Monoxide | 2 | 2012 | 64 | 0.130 |
Why?
| | ADAM Proteins | 1 | 2015 | 59 | 0.130 |
Why?
| | Lung Neoplasms | 1 | 2008 | 2220 | 0.130 |
Why?
| | Genetic Loci | 2 | 2016 | 281 | 0.130 |
Why?
| | Influenza, Human | 1 | 2021 | 554 | 0.130 |
Why?
| | Vital Capacity | 2 | 2012 | 260 | 0.130 |
Why?
| | Algorithms | 2 | 2019 | 1541 | 0.130 |
Why?
| | Blood Cells | 1 | 2014 | 39 | 0.130 |
Why?
| | Graft Rejection | 3 | 2007 | 555 | 0.130 |
Why?
| | Retrospective Studies | 10 | 2023 | 12978 | 0.120 |
Why?
| | Radiography | 2 | 2008 | 861 | 0.120 |
Why?
| | Gene Frequency | 3 | 2015 | 513 | 0.120 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 246 | 0.120 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2015 | 404 | 0.110 |
Why?
| | RNA, Messenger | 3 | 2012 | 2657 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2012 | 770 | 0.110 |
Why?
| | Scleroderma, Systemic | 1 | 2012 | 94 | 0.100 |
Why?
| | Diagnosis, Differential | 4 | 2019 | 1384 | 0.100 |
Why?
| | Promoter Regions, Genetic | 4 | 2019 | 1158 | 0.100 |
Why?
| | Phenotype | 3 | 2015 | 3003 | 0.100 |
Why?
| | Sensitivity and Specificity | 4 | 2019 | 1795 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 333 | 0.100 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2011 | 66 | 0.100 |
Why?
| | Aged, 80 and over | 5 | 2021 | 6561 | 0.100 |
Why?
| | Respiratory Function Tests | 3 | 2013 | 526 | 0.090 |
Why?
| | Gastroesophageal Reflux | 2 | 2003 | 248 | 0.090 |
Why?
| | Pulmonary Surfactants | 2 | 2007 | 98 | 0.090 |
Why?
| | Emergency Service, Hospital | 1 | 2021 | 1865 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 982 | 0.090 |
Why?
| | Severity of Illness Index | 3 | 2014 | 2674 | 0.090 |
Why?
| | Transplantation, Homologous | 2 | 2008 | 415 | 0.090 |
Why?
| | Postoperative Complications | 3 | 2006 | 2235 | 0.090 |
Why?
| | Prognosis | 3 | 2012 | 3443 | 0.080 |
Why?
| | Gene Expression | 4 | 2017 | 1489 | 0.080 |
Why?
| | Herpesvirus 8, Human | 1 | 2008 | 68 | 0.080 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2006 | 1137 | 0.080 |
Why?
| | Antibodies, Neoplasm | 1 | 2007 | 30 | 0.080 |
Why?
| | Burkholderia cepacia | 1 | 2007 | 1 | 0.080 |
Why?
| | Burkholderia Infections | 1 | 2007 | 5 | 0.080 |
Why?
| | Fatal Outcome | 1 | 2008 | 287 | 0.080 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2007 | 56 | 0.080 |
Why?
| | Telomerase | 2 | 2019 | 207 | 0.080 |
Why?
| | Sirolimus | 1 | 2008 | 195 | 0.080 |
Why?
| | Doxorubicin | 1 | 2008 | 302 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2013 | 2062 | 0.070 |
Why?
| | Viral Load | 1 | 2008 | 419 | 0.070 |
Why?
| | Disease Progression | 2 | 2012 | 2490 | 0.070 |
Why?
| | Drug Resistance, Bacterial | 1 | 2007 | 155 | 0.070 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2007 | 56 | 0.070 |
Why?
| | Prevalence | 3 | 2021 | 2326 | 0.070 |
Why?
| | Chromosome Mapping | 1 | 2007 | 510 | 0.070 |
Why?
| | Smoking | 3 | 2013 | 1487 | 0.070 |
Why?
| | Ganciclovir | 1 | 2004 | 46 | 0.060 |
Why?
| | Empyema | 1 | 2004 | 4 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 681 | 0.060 |
Why?
| | Aspergillus fumigatus | 1 | 2004 | 21 | 0.060 |
Why?
| | Opportunistic Infections | 1 | 2004 | 42 | 0.060 |
Why?
| | Aspergillosis | 1 | 2004 | 24 | 0.060 |
Why?
| | HLA Antigens | 1 | 2005 | 230 | 0.060 |
Why?
| | Sequence Analysis, DNA | 2 | 2019 | 755 | 0.060 |
Why?
| | Arthritis, Infectious | 1 | 2004 | 52 | 0.060 |
Why?
| | Genotype | 3 | 2013 | 1882 | 0.060 |
Why?
| | Lymphoproliferative Disorders | 1 | 2003 | 46 | 0.060 |
Why?
| | Logistic Models | 2 | 2019 | 1901 | 0.060 |
Why?
| | Linkage Disequilibrium | 2 | 2016 | 273 | 0.060 |
Why?
| | Antibodies | 1 | 2005 | 392 | 0.060 |
Why?
| | Triazoles | 1 | 2004 | 134 | 0.060 |
Why?
| | Fundoplication | 1 | 2003 | 56 | 0.060 |
Why?
| | Whole Genome Sequencing | 1 | 2023 | 113 | 0.050 |
Why?
| | Exome | 1 | 2023 | 220 | 0.050 |
Why?
| | Cytomegalovirus Infections | 1 | 2004 | 187 | 0.050 |
Why?
| | Lung Injury | 1 | 2004 | 210 | 0.050 |
Why?
| | Age Factors | 2 | 2006 | 2995 | 0.050 |
Why?
| | Paramyxoviridae Infections | 1 | 2021 | 10 | 0.050 |
Why?
| | Metapneumovirus | 1 | 2021 | 12 | 0.050 |
Why?
| | Rhinovirus | 1 | 2021 | 40 | 0.050 |
Why?
| | Picornaviridae Infections | 1 | 2021 | 29 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2007 | 1284 | 0.050 |
Why?
| | Survival Analysis | 3 | 2013 | 1267 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2019 | 1868 | 0.050 |
Why?
| | Activin Receptors, Type I | 1 | 2000 | 10 | 0.050 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2000 | 53 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2007 | 3730 | 0.050 |
Why?
| | Tracheal Diseases | 1 | 2000 | 16 | 0.050 |
Why?
| | Bronchial Diseases | 1 | 2000 | 34 | 0.050 |
Why?
| | Amyloidosis | 1 | 2000 | 40 | 0.050 |
Why?
| | Sex Factors | 1 | 2005 | 1781 | 0.050 |
Why?
| | Intensive Care Units | 1 | 2004 | 635 | 0.040 |
Why?
| | GTPase-Activating Proteins | 1 | 2019 | 71 | 0.040 |
Why?
| | Forced Expiratory Volume | 3 | 2007 | 520 | 0.040 |
Why?
| | Exoribonucleases | 1 | 2019 | 39 | 0.040 |
Why?
| | Pedigree | 2 | 2015 | 485 | 0.040 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2019 | 125 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2004 | 654 | 0.040 |
Why?
| | Enterovirus Infections | 1 | 2021 | 164 | 0.040 |
Why?
| | Telomere-Binding Proteins | 1 | 2019 | 87 | 0.040 |
Why?
| | Cystic Fibrosis | 1 | 2007 | 964 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 2 | 2012 | 842 | 0.040 |
Why?
| | Anti-Bacterial Agents | 1 | 2007 | 1510 | 0.040 |
Why?
| | Young Adult | 3 | 2021 | 10793 | 0.040 |
Why?
| | Fibrosis | 1 | 2020 | 483 | 0.040 |
Why?
| | Prospective Studies | 3 | 2019 | 6471 | 0.040 |
Why?
| | Physicians | 1 | 2006 | 794 | 0.040 |
Why?
| | Survival Rate | 3 | 2007 | 1720 | 0.040 |
Why?
| | Adolescent | 5 | 2021 | 18480 | 0.040 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2016 | 47 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 453 | 0.040 |
Why?
| | Coronavirus Infections | 1 | 2021 | 339 | 0.030 |
Why?
| | Herpesviridae | 1 | 2015 | 20 | 0.030 |
Why?
| | Syndrome | 2 | 2006 | 344 | 0.030 |
Why?
| | Asbestos | 1 | 1994 | 20 | 0.030 |
Why?
| | Bronchoalveolar Lavage | 1 | 2015 | 89 | 0.030 |
Why?
| | Ferric Compounds | 1 | 1994 | 39 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2015 | 81 | 0.030 |
Why?
| | Phagocytes | 1 | 1994 | 91 | 0.030 |
Why?
| | Heterozygote | 1 | 2015 | 262 | 0.030 |
Why?
| | Bleomycin | 2 | 2006 | 228 | 0.030 |
Why?
| | Genetic Markers | 1 | 2015 | 348 | 0.030 |
Why?
| | Total Lung Capacity | 1 | 2013 | 33 | 0.030 |
Why?
| | Animals | 6 | 2007 | 33381 | 0.030 |
Why?
| | Treatment Outcome | 5 | 2007 | 9342 | 0.030 |
Why?
| | Mice | 2 | 2007 | 15520 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 996 | 0.030 |
Why?
| | Chromosomes, Human | 1 | 2013 | 41 | 0.030 |
Why?
| | United States | 3 | 2021 | 12555 | 0.030 |
Why?
| | Telomere | 1 | 2015 | 204 | 0.030 |
Why?
| | DNA, Viral | 1 | 2015 | 356 | 0.030 |
Why?
| | Observer Variation | 1 | 2012 | 309 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2003 | 536 | 0.030 |
Why?
| | Wasp Venoms | 1 | 1991 | 4 | 0.030 |
Why?
| | Area Under Curve | 1 | 2011 | 296 | 0.020 |
Why?
| | Risk | 1 | 2013 | 853 | 0.020 |
Why?
| | Genetic Linkage | 1 | 2011 | 321 | 0.020 |
Why?
| | Aging | 1 | 2000 | 1670 | 0.020 |
Why?
| | Bayes Theorem | 1 | 2011 | 344 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4196 | 0.020 |
Why?
| | Regression Analysis | 1 | 2011 | 983 | 0.020 |
Why?
| | Pulmonary Alveoli | 1 | 1991 | 384 | 0.020 |
Why?
| | CD52 Antigen | 1 | 2007 | 3 | 0.020 |
Why?
| | Alemtuzumab | 1 | 2007 | 12 | 0.020 |
Why?
| | North Carolina | 1 | 2007 | 109 | 0.020 |
Why?
| | Colony Count, Microbial | 1 | 2007 | 120 | 0.020 |
Why?
| | Ontario | 1 | 2007 | 111 | 0.020 |
Why?
| | Chemokines, CXC | 1 | 2006 | 64 | 0.020 |
Why?
| | Chemokine CXCL12 | 1 | 2006 | 80 | 0.020 |
Why?
| | Receptors, CXCR4 | 1 | 2006 | 81 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2513 | 0.020 |
Why?
| | Antigens, Neoplasm | 1 | 2007 | 228 | 0.020 |
Why?
| | Glycoproteins | 1 | 2007 | 319 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2005 | 49 | 0.020 |
Why?
| | Blood Grouping and Crossmatching | 1 | 2005 | 16 | 0.020 |
Why?
| | Wnt Proteins | 1 | 2006 | 140 | 0.020 |
Why?
| | Antigens, CD | 1 | 2007 | 460 | 0.020 |
Why?
| | APACHE | 1 | 2004 | 61 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2004 | 210 | 0.010 |
Why?
| | Reoperation | 1 | 2006 | 557 | 0.010 |
Why?
| | Maximal Expiratory Flow Rate | 1 | 2003 | 2 | 0.010 |
Why?
| | Gastric Acidity Determination | 1 | 2003 | 7 | 0.010 |
Why?
| | Actuarial Analysis | 1 | 2003 | 23 | 0.010 |
Why?
| | Periodicals as Topic | 1 | 2006 | 191 | 0.010 |
Why?
| | Epidemiological Monitoring | 1 | 2003 | 49 | 0.010 |
Why?
| | Antifungal Agents | 1 | 2004 | 134 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 2004 | 144 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2007 | 667 | 0.010 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2004 | 128 | 0.010 |
Why?
| | Rats | 3 | 2000 | 5392 | 0.010 |
Why?
| | Immunocompromised Host | 1 | 2004 | 200 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 2 | 2000 | 2478 | 0.010 |
Why?
| | Wound Healing | 1 | 2004 | 270 | 0.010 |
Why?
| | Administration, Oral | 1 | 2004 | 756 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2007 | 984 | 0.010 |
Why?
| | Environmental Monitoring | 1 | 2003 | 296 | 0.010 |
Why?
| | Blotting, Northern | 1 | 2000 | 194 | 0.010 |
Why?
| | Embryonic and Fetal Development | 1 | 2000 | 95 | 0.010 |
Why?
| | Respiration, Artificial | 1 | 2004 | 545 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2006 | 2680 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 2000 | 311 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2003 | 1125 | 0.010 |
Why?
| | Fibroblasts | 1 | 2004 | 842 | 0.010 |
Why?
| | Tissue Distribution | 1 | 2000 | 334 | 0.010 |
Why?
| | Length of Stay | 1 | 2004 | 1032 | 0.010 |
Why?
| | Patient Readmission | 1 | 2004 | 634 | 0.010 |
Why?
| | Cells, Cultured | 2 | 2000 | 4077 | 0.010 |
Why?
| | Airway Obstruction | 1 | 2000 | 168 | 0.010 |
Why?
| | Animals, Newborn | 1 | 2000 | 806 | 0.010 |
Why?
| | Calcium | 2 | 1994 | 1169 | 0.010 |
Why?
| | Models, Biological | 1 | 2004 | 1715 | 0.010 |
Why?
| | Fetus | 1 | 2000 | 690 | 0.010 |
Why?
| | Asbestos, Crocidolite | 1 | 1994 | 1 | 0.010 |
Why?
| | Respiratory Burst | 1 | 1994 | 31 | 0.010 |
Why?
| | Chelating Agents | 1 | 1994 | 74 | 0.010 |
Why?
| | Magnesium | 1 | 1994 | 150 | 0.010 |
Why?
| | Epithelium | 1 | 1994 | 305 | 0.010 |
Why?
| | Inflammation | 1 | 2004 | 2566 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 6412 | 0.010 |
Why?
| | Superoxide Dismutase | 1 | 1994 | 339 | 0.010 |
Why?
| | Heart Failure | 1 | 2005 | 1969 | 0.010 |
Why?
| | Virulence Factors, Bordetella | 1 | 1991 | 20 | 0.010 |
Why?
| | Inositol Phosphates | 1 | 1991 | 23 | 0.010 |
Why?
| | Macrophages, Alveolar | 1 | 1994 | 359 | 0.010 |
Why?
| | Guanine Nucleotides | 1 | 1991 | 16 | 0.010 |
Why?
| | Pertussis Toxin | 1 | 1991 | 29 | 0.010 |
Why?
| | Arachidonic Acids | 1 | 1991 | 57 | 0.010 |
Why?
| | Type C Phospholipases | 1 | 1991 | 66 | 0.010 |
Why?
| | Rats, Inbred Strains | 1 | 1991 | 394 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2000 | 4596 | 0.010 |
Why?
| | Cyclic AMP | 1 | 1991 | 242 | 0.010 |
Why?
| | Protein Kinase C | 1 | 1991 | 297 | 0.010 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 1991 | 369 | 0.010 |
Why?
| | Neutrophils | 1 | 1994 | 1233 | 0.010 |
Why?
| | Oxidative Stress | 1 | 1994 | 1178 | 0.000 |
Why?
| | Kinetics | 1 | 1991 | 1624 | 0.000 |
Why?
| | Peptides | 1 | 1991 | 879 | 0.000 |
Why?
|
|
Steele's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|